Tzu‐Fei Wang

Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer

Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction

Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study

Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

Clinical implications of incidental venous thromboembolism in cancer patients

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

A cross-sectional analysis of cardiovascular disease in the hemophilia population

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Cancer-Associated Venous Thromboembolic Disease, Version 1.2015